Telefon Posted - 6 hours ago

$ELTP Elite Pharmaceuticals is on fire! It just received approval from the Israeli Ministry of Health to sell its generic version of Adderall through Dexcel Pharma. ELTP is now international and could expand into other foreign markets. The share price has risen 80% in the last two weeks, and the company is poised for more spectacular growth. The company is also waiting for FDA approval for generic Vyvanse and many other products with a total combined potential market value of over $6 billion. The CEO has stated his intention is for the company to be bought out within a year to two years. More unexpected catalysts could result in a higher SP and a buyout much sooner than that. Buy now while this is still under $1.00! $ZNTL $TTOO $AMGN $IONS

swingingtech Posted - 8 hours ago

$PHM $CI $AMGN https://wallstreetwaves.com/highlighting-mondays-key-options-trades-spotlight-on-phm-ci-amgn/

biolover Posted - 11 hours ago

$Vktx $Rhhby $amgn Roche running now phase 2 trials on their glp1 drug for finish in 2026. Phase 3 will not start till late 26 or 2027. That means Roche is now minimum 1.5 years behind Viking with a drug that is more toxic and potentially even less effective The big bust will unfold later this year with Amgen likely disappointing data . They have not even commented on a date for phase 3

twiney Posted - 13 hours ago

$AMGN has alerted for a potential move lower. Target is set for 313.49. Will need some volume or wind from the market for this move.

clan Posted - 1 day ago

$MNKD For Mannkind, here are some clear reasons to hold on for dear life [HODL]... with diamond hands! $AMGN $LLY $SNY

PIVOTPOINTSMUSA Posted - 2 days ago

$CAT $COIN $META $HUM $AMGN 10/30 ER meet me there 🫡

GemsBot Posted - 2 days ago

1 of 11 $AAPL $AMGN $AMZN Daily and 30 min charts of the DJIA Components with the SSI indicator, a proprietary indicator based exclusively on the eSignal platform, are posted here weekends … see 2/11

Vmousaei1 Posted - 3 days ago

$AMGN anyone thinks this will beat earnings?

Canyon_Partners Posted - 3 days ago

$AMGN $ESPR Esperion has got to be one of the most undervalued stocks people can buy. Profitable in 2025, Prescriptions growth will continue $LW activist investor pushing for a sale. ESPR has serious buyout potential because it sells the only statin alternative oral pill FDA approved within the last 20 years with a primary prevention label. The earnings power ESPR has is huge. I the the drug NEXLIZET, now my insurance covers it.

MooreKuehn Posted - 4 days ago

$AMGN https://www.globenewswire.com/news-release/2024/10/02/2957395/0/en/Moore-Law-PLLC-Encourages-Amgen-Inc-Investors-to-Contact-Law-Firm.html

IN0V8 Posted - 4 days ago

$AMGN Bernstein initiates coverage with outperform rating; PT $380

erevnon Posted - 4 days ago

Bernstein initiates coverage on Amgen $AMGN at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

DrBenGalper Posted - 5 days ago

$AMGN Amgen corporate, I do hope you are reviewing Repatha prescriptions data out of Kaiser? I heard that now 74 patients have moved off Repatha and onto Nexlizet in the last few weeks at my location, I expect the trend to continue. Repatha no hs-CRP reduction when compared to Nexlizet & similar LDLc reduction. Nexlizet advantages for Kaiser savings on drug cost along with NO need for bi-weekly doctor appointments. Time to partner or buyout Esperion Therapeutics is now. Offer Esperion $2 billion of AMGN stock and benefit from the $1.6 billion in tax write off on the Esperion balance sheet. Esperion has patents solid until 2031, also ext to 2040. Future milestones are $900 million, with $140 million do next year from Otsuka, that will also pay 30% in royalties. Daiichi Sankyo Europe will be paying over $500 million in royalties per year by 2029 to Esperion. Amgen don't miss this opportunity to acquire Esperion now.

DrBenGalper Posted - 5 days ago

$AMGN Amgen corporate, I do hope you are reviewing Repatha prescriptions data out of Kaiser? I heard that now 74 patients have moved off Repatha and onto Nexlizet in the last few weeks at my location, I expect the trend to continue. Repatha no hs-CRP reduction when compared to Nexlizet & similar LDLc reduction. Nexlizet advantages for Kaiser savings on drug cost along with bi-weekly doctor appointments. Time to partner or buyout Esperion Therapeutics is now.

DrRefa Posted - 5 days ago

$AMGN anyone has results of PH2 abp 206?

tedevan Posted - 6 days ago

$AMGN $MRK $ESPR

Canyon_Partners Posted - 6 days ago

$ESPR I think $AMGN or $MRK or some other BIG Pharma needs to make a move to acquire Esperion now. https://docwirenews.com/post/bempedoic-acid-in-line-with-statins-for-reducing-ldl-c

Quantumup Posted - 6 days ago

Cantor Fitzgerald🏁 $IDYA OW, says its DD suggests daro' can be a practice-changing Tx for UM—its model suggests the shares r undervalued=34%: Goldman Sachs reit $IDYA Buy/$48 +⬆️daro' unadjd peak sales ests to $3B was $2.6B, after recent +VE UM data: $pfe $tngx $bmy $amgn azn

briefingcom Posted - 6 days ago

$AMGN: Amgen presents positive phase 3 data for Uplizna (inebilizumab-cdon) in generalized myasthenia gravis (gmg) at AANEM 2024

DefenseMania Posted - 6 days ago

$ABBV don’t miss the breakout on GILD $PFE $AMGN $LLY

DonCorleone77 Posted - 6 days ago

$AMGN Amgen announces 'positive' Phase 3 data for UPLIZNA Amgen announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA for the treatment of adults with generalized myasthenia gravis, a rare autoimmune disorder. Results from this randomized, double-blind, placebo-controlled, parallel-group trial will be presented at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, taking place Oct. 15-18 in Savannah, Georgia. The trial met its primary endpoint, with a statistically significant change from baseline in Myasthenia Gravis Activities of Daily Living score for UPLIZNA (-4.2) compared with placebo (-2.2) at Week 26 for the combined study population. The study included patients who are acetylcholine receptor autoantibody-positive (AChR+) and those who are muscle-specific kinase autoantibody-positive (MuSK+), with participants receiving UPLIZNA or placebo on Day 1 and Day 15. UPLIZNA demonstrated continued improvement through Week 26. Notably, patients who entered the study taking corticosteroids were tapered down starting at Week 4 to prednisone 5 mg per day by Week 24. No new safety signals were identified.

popculture Posted - 1 week ago

$AMGN Devarakonda downgraded shares to a hold rating from buy, but raised her price target to 333 from 320. This biitchh is weird to say the least

Stocksrunner Posted - 1 week ago

📈 Big analyst moves today! 🚨 Check out the latest upgrades and downgrades shaking up the market. Can $AFRM bounce back with its fresh Neutral rating? Will $AMGN obesity drug lose steam? And what about $ATR upgrade to Buy? Dive in for more on $CAT and $ACLX hitting key price targets! 👀 stocksrunner.com/posts/1254

Canyon_Partners Posted - 1 week ago

Excellent video clip, but now FDA primary prevention label makes it a lot easier to get on the drug. $AMGN $ESPR Wonder if $REGN would be interested in buying ESPR? the current market cap of $400 mm along with $900mm in future milestones, $140mm being paid next year & royalties starting from Otsuka, 3 new countries expected to start selling ESPR statin alternative drugs NEXLIZET & NEXLETOL.

Thestocktraderhubzee Posted - 1 week ago

$AMGN Truist Securities Downgrades Amgen to Hold, Raises Price Target to $333

ksoption Posted - 1 week ago

$ADBE $MSFT $AMGN

IN0V8 Posted - 1 week ago

$AMGN Truist Securities cuts to hold from buy; raises PT to $333 from $320

TheStockTraderHub Posted - 1 week ago

PART 2 : TD Cowen reiterates Nvidia as buy Goldman Sachs reiterates Alphabet as buy Truist downgrades Amgen to hold from buy Piper Sandler reiterates Tesla as overweight Oppenheimer reiterates Walmart as a top pick $NVDA $AMGN $TSLA $WMT $GOOGL

theflynews Posted - 1 week ago

Truist downgrades Amgen with obesity potential priced into shares - $AMGN - https://thefly.com/permalinks/entry.php/AMGNid3997468